hydroxychloroquine has been researched along with Herpes Zoster in 5 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Herpes Zoster: An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine was protective of mortality from serious infections (HR 9." | 1.48 | Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. ( Ling, GR; Teh, CL; Wan, SA, 2018) |
| " Cases (1555 patients with SLE who developed HZ) and controls (3049 age- and sex-matched patients with SLE but without HZ) were analyzed for use of various immunosuppressive medications in the preceding 3-month period, and dose-response relationships were determined." | 1.43 | Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. ( Chen, GS; Hu, SC; Lin, CL; Lin, YC; Wang, TN; Yen, FL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teh, CL | 1 |
| Wan, SA | 1 |
| Ling, GR | 1 |
| Zisman, D | 1 |
| Bitterman, H | 1 |
| Shalom, G | 1 |
| Feldhamer, I | 1 |
| Comanesther, D | 1 |
| Batat, E | 1 |
| Greenberg-Dotan, S | 1 |
| Cohen, S | 1 |
| Cohen, AD | 1 |
| Hu, SC | 1 |
| Yen, FL | 1 |
| Wang, TN | 1 |
| Lin, YC | 1 |
| Lin, CL | 1 |
| Chen, GS | 1 |
| Hirbod, T | 1 |
| Altamura, D | 1 |
| Arkoumani, E | 1 |
| Stefanato, CM | 1 |
| Verdolini, R | 1 |
| Liao, TL | 1 |
| Chen, YM | 1 |
| Liu, HJ | 1 |
| Chen, DY | 1 |
5 other studies available for hydroxychloroquine and Herpes Zoster
| Article | Year |
|---|---|
Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality.
Topics: Adult; Bacterial Infections; Candidiasis; Enzyme Inhibitors; Female; Herpes Zoster; Hospitalization; | 2018 |
Psoriatic arthritis treatment and the risk of herpes zoster.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Azathioprine; Cyclosporine; Dru | 2016 |
Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
Topics: Administration, Intravenous; Administration, Oral; Adrenal Cortex Hormones; Adult; Azathioprine; Cas | 2016 |
Discoid lupus erythematosus occurring in an area previously affected by herpes zoster virus: Wolf's isotopic reaction?
Topics: Aged; Antiviral Agents; Dermatologic Agents; Drug Therapy, Combination; Herpes Zoster; Herpesvirus 3 | 2017 |
Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Topics: Abatacept; Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Mon | 2017 |